Attracting up-and-coming talent in biotech

The CEO of a Bay-area startup shares his strategies for growing a team from the ground up.

By Meagan Parrish • May 3, 2023

From science to strategy, this exec is painting Genmab’s bigger picture into the next decade

Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of "knock your socks off" antibodies.

By Michael Gibney • May 2, 2023

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Taking your biotech global? Here’s how you can navigate cultural norms

What’s so different about doing pharma business in the U.K. versus Japan? One of Moderna’s top brass shares her tips for navigating choppy cultural waters.

By Alexandra Pecci • May 2, 2023

Emalex aims at a first-in-class breakthrough for Tourette syndrome

With its phase 3 candidate, the biotech believes it can move the field beyond antipsychotics to a more effective approach.

By Kelly Bilodeau • May 1, 2023

A CEO’s quest to solve a 400-year-old medical mystery — and he’s also a patient

The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.

By Taren Grom • May 1, 2023

How biopharma dealmaking kicked back into action

Events over the last year, including Pfizer’s Seagen buy and AstraZeneca’s CinCor deal, have foreshadowed the comeback of biopharma M&A.

By Michael Gibney • April 27, 2023

Pharma’s immunology field is full of blockbusters, and it’s just getting started

From the "father" of the IL-23 pathway at Janssen to a big acquisition by Merck, the ultra-competitive immunology space is still growing with the pace of innovation.

By Michael Gibney • April 27, 2023

Scientists could finally be closing in on a ‘pill’ for men

Drug developers have tried — and failed — to create a male contraceptive for decades. Now, one group of scientists might be on the verge of success.

By Kelly Bilodeau • April 26, 2023

Roy Vagelos is retiring and leaving a legacy of leadership lessons

The longtime pharma leader is stepping down from his role as chair of Regeneron’s board in June after decades in drug development. 

By Karissa Waddick • April 25, 2023

20 years on, the next stage of the human genome revolution is brewing

Two decades after the Human Genome Project, scientists are on the brink of uncovering its full potential for drug development.

By Karissa Waddick • April 24, 2023

Cure Ventures has $350M to pour deep into biotech ‘company building’

The biotech venture capital firm Cure Ventures, led by three industry veterans, raised the inaugural fund in early April and will soon announce its seed companies.

By Michael Gibney • April 20, 2023

Woman of the Week: Brii Biosciences’ Ellee de Groot

A chemical engineer by training, Brii’s chief technology officer is applying her experience to solve research problems from the clinic to commercial development.

By Taren Grom • April 19, 2023

Conditions for worker burnout in biotech are ripe. Here’s how to beat it

One of the country’s leading burnout experts explains how companies can help keep high stress from becoming a high desire to leave the job.

By Meagan Parrish • April 19, 2023

A CMO’s quest to tackle infectious diseases leads him to an eye condition that’s often overlooked

How an “international” childhood sent Dr. José Trevejo, Tarsus’s chief medical officer, on a mission to fight infectious diseases.

By Alexandra Pecci • April 18, 2023

Depression has long been treated chronically — Sage wants to change that

Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.

By Michael Gibney • April 18, 2023

A new era of COVID innovation is here

With a $5 billion dollar infusion, a new White House program is helping catalyze development of next-gen treatments, from pan-coronavirus vaccines to enhanced antivirals. 

By Kelly Bilodeau • April 17, 2023

5 minutes with — Genlantis Diagnostics’ Ahsan Awan

A serial entrepreneur, futurist and industry disrupter, the VP of clinical development and digital health is always on the quest to build a “better mousetrap.”

By Taren Grom • April 14, 2023

He helped launch the Pfizer COVID vaccine — now this startup CEO is hunting a lingering pandemic foe

All of the COVID-19 mAbs have been pulled from the market. But Dave Hering, CEO of Invivyd, hopes to change that.

By Meagan Parrish • April 11, 2023

Where one unicorn struggled, another biotech is aiming for a diabetes win

Intarcia looked poised to break into a lucrative diabetes implant market but has been dogged by safety issues — now Vivani thinks it’s found a way to succeed.

By Kelly Bilodeau • April 10, 2023

A drug just launched for a disease discovered only 10 years ago

Pharming just landed an FDA approval for a treatment targeting an ultra-rare immunodeficiency disorder discovered only a decade ago — and it’s already in the hands of patients.

By Karissa Waddick • April 6, 2023

Despite J&J’s exit, Big Pharma is closing in on a launch of the first RSV vax this year

Although Janssen bowed out of the RSV vaccine race, several pharmas are quickly closing in on the finish line in a disease with decades of unmet need.

By Michael Gibney • April 6, 2023

Woman of the Week: Intergalactic Therapeutics’ Dr. Theresa Heah

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Dr. Theresa Heah has spent her entire career moving ophthalm...

By Taren Grom • April 5, 2023

Moderna exec: ‘There is nothing but global health’

How Chantal Friebertshäuser is helping lead Moderna’s plan to expand its global reach.  

By Alexandra Pecci • April 4, 2023

The silver linings in biotech’s wobbly market

A report from accounting firm BDO compares biotech’s tough times with the booming last few years — and points to some silver linings.

By Michael Gibney • April 4, 2023

All eyes turn to Karuna as it aims for an approval of a would-be blockbuster

In the red-hot race for new schizophrenia treatments, Karuna Therapeutics is close to an FDA submission.

By Kelly Bilodeau • April 3, 2023